Purebase Corp 8-K, filed Aug 17, 2021
Purebase Corp (PUBC)
About this 8-K
Purebase Corp filed this 8-K on August 17, 2021, reporting on events of August 10, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 10, 2021
PUREBASE CORPORATION
(Exact name of registrant as specified in charter)
| Nevada | 000-55517 | 27-2060863 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
8625 State Hwy, 124
Ione, CA 95640
(Address of principal executive offices)
(855) 743-6478
(Registrant’s telephone number, including area code)
| N/A |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective August 10, 2021, Dr. Kimberly Kurtis was appointed to serve on the Board of Directors of Purebase Corporation (the “Company”) as an independent member.
Dr. Kurtis, age 49, is an Associate Dean and a professor in the School of Civil and Environmental Engineering at Georgia Institute of Technology (“Georgia Tech”). Dr. Kurtis joined Georgia Tech’s faculty in January 1999. Dr. Kurtis has served as Georgie Tech’s ADVANCE Professor from 2012 to 2014, and she holds a courtesy appointment in the School of Materials Science and Engineering. Dr. Kurtis earned a BSE in Civil Engineering in 1994 from Tulane University under a Dean’s Honor Scholarship, and she received a M.S. in 1995 and PhD in 1998 in Civil Engineering from the University of California at Berkeley, where she was a Henry Hilp Fellow and a National Science Foundation Fellow. Dr. Kurtis’s research on the multi-scale structure and performance of cement-based materials has resulted in more than 200 technical publications and three U.S. patents.
Dr. Kurtis was selected as a director for, among other things, her expertise in the development of supplementary cementitious materials.
The Company entered into a twelve-month director agreement with Dr. Kurtis, effective August 13, 2021 (the “Agreement”), which will automatically renew unless Dr. Kurtis gives 30 days prior notice of her desire not to renew the Agreement. Pursuant to the Agreement, Dr. Kurtis will be paid $1,000 per month for serving as a director, which shall accrue as debt until the Company has its first cash flow positive month. At the completion of the term of the Agreement or if Dr. Kurtis has been removed or resigned, any accrued amount owed will be paid in shares of the Company’s common stock at the lower of $0.15 per share or the 20-day volume weighted average price from the date of termination or resignation.
On August 13, 2021, Dr. Kurtis was granted a five-year option to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.36 per share pursuant to an option agreement with the Company (the “Option Agreement”). Shares subject to the option become exercisable one year from the date of grant.
There are no arrangements or understandings between Dr. Kurtis and any other person pursuant to which she was appointed as a director of the Company. There are no family relationships between Dr. Kurtis and any of the Company’s other officers or directors, or transactions since January 1, 2021, or any currently proposed transaction, in which the Company is a participant, the amount involved exceeds $120,000, and in which Dr. Kurtis had, or will have, a direct or indirect material interest, other than as described above.
The foregoing description of the Agreement and the Option Agreement is qualified in its entirety by reference to the full text of the Agreement and the Option Agreement, copies of which are attached hereto as Exhibit 10.15 and Exhibit 10.16, respectively, and are incorporated herein in their entirety by reference.
Item 7.01 Regulation FD Disclosure.
On August 13, 2021, the Company issued a press release announcing the appointment of Dr. Kurtis as a director. A copy of the press release is filed as Exhibit 99.1 to this Report and incorporated herein by reference.
The information in this Item 7.01 of this Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Report in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description of Exhibit | |
| 10.15 | Director Agreement, dated as of August 13, 2021, between the Company and Kimberly Kurtis | |
| 10.16 | Option Agreement, dated August 13, between the Company and Kimberly Kurtis | |
| 99.1 | Press Release dated August 13, 2021 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: August 17, 2021 | PUREBASE CORPORATION | |
| By: | /s/ A. Scott Dockter | |
A. Scott Dockter Chief Executive Officer | ||
Exhibit 10.15
DIRECTOR AGREEMENT
THIS AGREEMENT (The “Agreement”) is effective as of the 13th day of August 2021, and is by and between Purebase Corporation, a Nevada corporation (hereinafter referred to as the “Company”), and Dr. Kimberly Kurtis (hereinafter referred to as the “Director”).
BACKGROUND
Each of the Board of Directors of the Company and the Director desires to memorialize the role of the Director and to have the Director perform the duties required of such position in accordance with the terms and conditions of this Agreement.
AGREEMENT
NOW THEREFORE, in consideration for the above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged, the Company and the Director hereby agree as follows:
| 1. | DUTIES. The Company requires that the Director be available to perform the duties of a director customarily related to this function as may be determined and assigned by the Board of Directors of the Company and as may be required by the Company’s constituent instruments, including its certificate or articles of incorporation, bylaws and its corporate governance and board committee charters, each as amended or modified from time to time, and by applicable law, including by the Nevada Revised Statutes (the “NRS”). |
The Director agrees to devote as much time as is necessary to perform completely the duties as the Director of the Company, including duties as a member of any committees as the Director may hereafter be appointed to by the Board of Directors.
The Director will perform such duties described herein in accordance with the general fiduciary duty of directors arising under the NRS. Such duties include but are not limited to assisting the Company with the development of business and new business strategies relating to the objectives of the Company, participation in the Company’s investor relations activities including road shows and shareholder communication activities, and participation in corporate strategy decisions of the Company.
The commitment of Dr. Kurtis’ time and efforts towards board duty responsibilities will be five (5) hours maximum per month.
| 2. | TERM. The term of this engagement shall be for twelve (12) months from the date of this Agreement (the “Term”), or until the Director’s removal or resignation. The term is renewed unless Purebase gives Dr. Kurtis 30 days’ notice not to renew. |
| 1 |
| 3. | COMPENSATION. For all services to be rendered by the Director in any capacity hereunder, the Company agrees to pay the Director a combination of cash and stock. |
| ■ | Cash Fees: Dr. Kurtis shall receive a fee of $1,000.00 per month in cash. This fee shall accrue as debt to the Company until the Company has its first cash-flow positive month. At this point, the Company shall make arrangements to pay Dr. Kurtis the debt owed to her for these services. If a debt is still owed to Dr. Kurtis when the original Term is completed, or she has been removed or she has resigned, then the Debt owed to Dr. Kurtis shall be converted into common stock at the lower of price of $0.15 or the 20-day WVAP closing from the last date of Dr. Kurtis being on the board. The Company shall convert the Kurtis Debt and issue to Dr. Kurtis shares of common stock of the Company within 10 business days of the completion of the original Term, his removal or his resignation. |
| ■ | Equity Fees: Within 10 days upon signing of this contract, Dr. Kurtis shall be granted (two hundred thousand) 200,000 stock options that have a strike price of $0.36. These options will be exercisable for a period of 5 years from the effective date. These stock options are not transferable to another party and Dr. Kurtis will be subject to all the SEC reporting requirements associated with the grant, exercise and sale of this equity compensation. |
| 4. | EXPENSES. In addition to the compensation provided in paragraph 3 hereof, the Company will reimburse the Director for pre-approved reasonable business-related expenses incurred in good faith in the performance of the Director’s duties for the Company. Such payments shall be made by the Company upon submission by the Director of a signed statement itemizing the expenses incurred. Such statement shall be accompanied by sufficient documentary matter to support the expenditures. |
| 5. | CONFIDENTIALITY. The Company and the Director each acknowledge that, in order for the intents and purposes of this Agreement to be accomplished, the Director shall necessarily be obtaining access to certain confidential information concerning the Company and its affairs, including, but not limited to business methods, information systems, financial data and strategic plans which are unique assets of the Company (“Confidential Information”). The Director covenants not to, either directly or indirectly, in any manner, utilize or disclose to any person, firm, corporation, association or other entity any Confidential Information. |
| 6. | NON-COMPETE. During the term of this Agreement and for a period of twelve (12) months following the Director’s removal or resignation from the Board of Directors of the Company or any of its subsidiaries or affiliates (the “Restricted Period”), the Director shall not, directly or indirectly, (i) in any manner whatsoever engage in any capacity with any business competitive with the Company’s current lines of business or any business then engaged in by the Company, any of its subsidiaries or any of its affiliates (the “Company’s Business”) for the Director’s own benefit or for the benefit of any person or entity other than the Company or any subsidiary or affiliate; or (ii) have any interest as owner, sole proprietor, shareholder, partner, lender, director, officer, manager, employee, consultant, agent or otherwise in any business competitive with the Company’s Business; provided, however, that the Director may hold, directly or indirectly, solely as an investment, not more than two percent (2%) of the outstanding securities of any person or entity which are listed on any national securities exchange or regularly traded in the over-the-counter market notwithstanding the fact that such person or entity is engaged in a business competitive with the Company’s Business. In addition, during the Restricted Period, the Director shall not develop any property for use in the Company’s Business on behalf of any person or entity other than the Company, its subsidiaries and affiliates. It has been approved for Dr. Kurtis to be an advisor and or consultant for Sublime and to continue her research and consulting projects with Georgia Tech. |
| 2 |
| 7. | TERMINATION. With or without cause, the Company and the Director may each terminate this Agreement at any time upon 5 (five) days written notice, and the Company shall be obligated to pay to the Director the compensation and expenses due up to the date of the termination. Nothing contained herein or omitted here from shall prevent the shareholder(s) of the Company from removing the Director with immediate effect at any time for any reason. |
| 8. | INDEMNIFICATION. The Company shall indemnify, defend and hold harmless the Director, to the full extent allowed by the law of the State of Nevada and as provided by, or granted pursuant to, any charter provision, bylaw provision, vote of stockholders or disinterested directors or otherwise, to action in the Director’s official capacity; provided, however, that, in accordance with the NRS and federal securities laws, such indemnification shall not apply where the Director engages in actions or omissions which involve intentional misconduct, fraud or knowing violation of law. |
| 9. | NOTICE. Any and all notices referred to herein shall be sufficient if furnished in writing at the addresses specified on the signature page hereto or, if to the Company, to the Company’s address as specified in filings made by the Company with the U.S. Securities and Exchange Commission. |
| 10. | GOVERNING LAW. This Agreement shall be interpreted in accordance with, and the rights of the parties hereto shall be determined by, the laws of the State of Nevada without reference to that state’s conflicts of laws principles. |
| 11. | ASSIGNMENT. The rights and benefits of the Company under this Agreement shall be transferable, and all the covenants and agreements hereunder shall inure to the benefit of, and be enforceable by or against, its successors and assigns. The duties and obligations of the Director under this Agreement are personal and therefore the Director may not assign any right or duty under this Agreement without the prior written consent of the Company. |
| 12. | GENERAL. |
| a. | SEVERABILITY. If any provision of this Agreement shall be declared invalid or illegal, for any reason whatsoever, then, notwithstanding such invalidity or illegality, the remaining terms and provisions of this Agreement shall remain in full force and effect in the same manner as if the invalid or illegal provision had not been contained herein. |
| b. | EFFECT OF WAIVER. The waiver by either party of the breach of any provision of this Agreement shall not operate as or be construed as a waiver of any subsequent breach thereof. |
| c. | ARTICLE HEADINGS. The article headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. |
| d. | COUNTERPARTS. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one instrument. Facsimile execution and delivery of this Agreement is legal, valid and binding for all purposes. |
| e. | ENTIRE AGREEMENT. Except as provided elsewhere herein, this Agreement sets forth the entire agreement of the parties with respect to its subject matter and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party to this Agreement with respect to such subject matter. |
[Remainder of Page Left Blank Intentionally]
| 3 |
IN WITNESS WHEREOF, the parties have executed this Agreement as of August 13, 2021.
| PUREBASE CORPORATION | ||
| By: | /s/ A. Scott Dockter | |
| Name: | A. Scott Dockter | |
| Title: | Chief Executive Officer | |
| GRANTEE: | ||
| /s/ Kimberly Kurtis | ||
| Name: | Kimberly Kurtis | |
| Address: | ||
| 805 Adair Avenue, NE | ||
| Atlanta, GA 30306 | ||
| Kimberly.kurtis@gmail.com | ||
| Cell: (404) 509- 5984 | ||
| 4 |
Exhibit 10.16
THE OPTION GRANTED PURSUANT TO THIS AGREEMENT AND THE SECURITIES ISSUABLE UPON THE EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY STATE BLUE SKY OR SECURITIES LAWS IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND BLUE SKY LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR QUALIFICATION, OR AN EXEMPTION FROM THE REGISTRATION OR QUALIFICATION REQUIREMENTS OF SUCH ACT OR LAWS.
PUREBASE CORPORATION
OPTION AGREEMENT
Section 1. Definitions.
Capitalized terms used herein shall have the meanings set forth below.
“Agreement” shall mean this Option Agreement.
“Company” shall mean Purebase Corporation, a Nevada corporation.
“Date of Grant” shall mean the date specified in the Notice of Option Grant.
“Grantee” or “Optionee” means the individual named in the Notice of Option Grant attached to this Agreement.
“Notice of Option Grant” means the Notice of Option Grant dated the date hereof granted to the Grantee.
“Securities Act” shall mean the Securities Act of 1933, as amended.
“Shares” or “Stock” shall mean the Common Stock of the Company.
“Transfer” shall mean any direct or indirect sale, assignment, transfer, gift, pledge, encumbrance or other disposition.
Section 2. Grant of Option.
Subject to the terms and conditions set forth in the Notice of Option Grant and this Agreement, the Company hereby grants to the Grantee the option to purchase the number of Shares indicated in the Notice of Option Grant. The grant to the Grantee is personal and cannot be Transferred without the prior written consent of the Company.
Section 3. Right to Exercise.
3.1 Subject to the other provisions contained in this Agreement and the Notice of Option Grant, the option may be exercised at any time by delivery of notice to the Company and payment of the applicable exercise price. The Grantee or the Grantee’s authorized representative may exercise this option by giving written notice to the Company. The notice shall be signed by the person exercising this option and if the option is being exercised by the representative of the Grantee, the notice shall be accompanied by proof satisfactory to the Company of the representative’s right to exercise this option.
| -1- |
3.2 In the event that the Company determines that it is required to withhold any tax as a result of the exercise of this option, the Grantee, as a condition to the exercise of this option, shall make arrangements satisfactory to the Company to enable it to satisfy all federal, state and local withholding requirements. The Optionee shall also make arrangements satisfactory to the Company to enable it to satisfy any withholding requirements that may arise in connection with the vesting or disposition of Shares issued in connection with exercising this option.
Section 4. Representations and Warranties.
Recognizing that the Company will be relying on the information and on the representations and warranties set forth herein, the Grantee hereby acknowledges, represents and warrants to, and agrees with, the Company to the representations and warranties set forth below, which shall be true and correct as of the date hereof and upon each date that the Grantee exercises the option.
(a) I represent and warrant that I am acquiring and will hold the option and the Shares received upon exercise of such option for investment for my account only, and not with a view to, or for resale in connection with, any “distribution” of the option and the Shares within the meaning of the Securities Act.
(b) I understand that the option and the Shares have not been registered under the Securities Act or any state securities laws by reason of a specific exemption therefrom and that the option and the Shares must be held indefinitely, unless they are subsequently registered under the Securities Act or I obtain an opinion of counsel (in form and substance satisfactory to the Company and its counsel) that registration is not required.
(c) I acknowledge that the Company is under no obligation to register the option or the Shares subject to the Option.
(d) I am aware of the adoption of Rule 144 by the Securities and Exchange Commission under the Securities Act, which permits limited public resales of securities acquired in a non-public offering, subject to the satisfaction of certain conditions. These conditions include (without limitation) that certain current public information about the issuer is available, that the resale occurs only after the holding period required by Rule 144 has been satisfied, that the sale occurs through an unsolicited “broker’s transaction” and that the amount of securities being sold during any three-month period does not exceed specified limitations.
(e) I will not Transfer or otherwise dispose of the option and the Shares subject thereto in violation of the Securities Act, the Securities Exchange Act of 1934, or the rules promulgated thereunder, including Rule 144 under the Securities Act or any blue sky or state securities laws or regulations.
| -2- |
(f) I acknowledge that I have received and had access to such information as I consider necessary or appropriate for deciding whether to invest in the option and the Shares subject thereto and that I had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the issuance of the option and the Shares subject thereto.
(g) I am aware that my investment in the Company is speculative and subject to the risk of complete loss.
(h) I acknowledge that I am an “accredited investor”, as such term is defined under the Securities Act.
(i) I acknowledge that I am acquiring the option and the Shares subject thereto to all the terms of the Notice of Grant and this Agreement.
Section 5. Miscellaneous.
5.1 This Agreement and the rights and obligations hereunder are not transferable or assignable by the Grantee.
5.2 This Agreement and the rights, powers and duties set forth herein shall be binding upon and inure to the benefit of the heirs, executors, administrators, successors, legal representatives and permitted successors and assigns of the parties hereto.
5.3 Neither this Agreement nor any provisions hereof shall be waived, modified, discharged or terminated except by an instrument in writing signed by the party against whom any such waiver, modification, discharge or termination is sought.
5.4 Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be mailed by certified mail, return receipt requested, nationally recognized overnight delivery service or by hand to (a) the Optionee at his address on the books of the Company, and (b) to the Company, at its principal address. Any notice or other communications given by certified mail shall be deemed given at the time of certification thereof, except for a notice changing a party’s address, which shall be deemed given at the time of receipt thereof.
5.5 This Agreement shall be deemed to have been made under, and shall be governed by, and construed in accordance with, the substantive laws of the State of Nevada (excluding the law thereof which requires the application of or reference to the law of any other jurisdiction).
5.6 This Agreement, may be signed in counterparts and by facsimile or other electronic means, each of which shall be an original, and both of which shall together constitute one and the same instrument.
| -3- |
IN WITNESS WHEREOF, the parties have executed this Agreement as of August 13, 2021.
| PUREBASE CORPORATION | ||
| By: | /s/ A. Scott Dockter | |
| Name: | A. Scott Dockter | |
| Title: | Chief Executive Officer | |
| GRANTEE: | ||
| /s/ Kimberly Kurtis | ||
| Dr. Kimberly Kurtis | ||
| -4- |
PUREBASE CORPORATION
NOTICE OF OPTION GRANT
Purebase Corporation (the “Company”) is pleased to advise you that pursuant to the attached Option Agreement you have been granted the following options to purchase shares of common stock of the Company:
|
Name of Grantee: |
Dr. Kimberly Kurtis |
| Number of Shares: | 200,000 |
| Date of Grant: | August 10, 2026 |
| Exercise Price: | $0.38 |
| Expiration Date: | August 10, 2026 |
| Vesting Schedule: | All options granted hereunder shall be immediately exercisable. |
By your signature and the signature of the Company, you and the Company agree that this option is granted under and governed by the terms and conditions of the Option Agreement, which is attached to and made a part of this document.
| GRANTEE: | PUREBASE CORPORATION | |||
| /s/ Kimberly Kurtis | By: | /s/ A. Scott Docter | ||
| Name: | Dr. Kimberly Kurtis | Name: | A. Scott Dockter | |
| Title: | Chief Executive Officer | |||
Address:
805 Adair Ave, NE
Atlanta, GA 30306
[personal email address]
Cell: (XXX) XXX-XXXX
Social Security Number: XXX-XX-XXXX
| -5- |
Exhibit 99.1
Purebase Welcomes Dr. Kimberly Kurtis to the Board of Directors
IONE, CA, August 13, 2021 - Purebase Corporation (OTCQB: PUBC), a diversified resource company, headquartered in Ione, California, is pleased to announce the appointment of Dr. Kimberly Kurtis to the Purebase Board of Directors. For the past year, Dr. Kurtis has been serving as an Advisory Board Member.
Dr. Kurtis’s innovative research on the multi-scale structure and performance of cement-based materials has resulted in more than 200 technical publications, as well as three US patents. Her group is particularly recognized its use of emerging methods and novel approaches to provide new fundamental insights into the behavior of cement pastes, mortars, and concretes necessary for improving their early age behavior and long-term durability.
Purebase’s Chairman and CEO, Scott Dockter stated, “We have been very impressed with her guidance in the development of our supplementary cementitious materials (SCMs) and feel her critical thinking skills and leadership will advance the goals of Purebase.”
Dr. Kimberly Kurtis is Associate Dean for Faculty Development and Scholarship in the College of Engineering, where she manages the reappointment, tenure, peer review, and selection processes for the College’s faculty and researchers, leads faculty development initiatives, and assists with management of faculty hiring strategies and inclusion programs. She is a Professor in the School of Civil and Environmental Engineering at Georgia Institute of Technology, serving as interim Chair in the school (2017-18) and as the College’s ADVANCE Professor (2012-14), and holds a courtesy appointment in the School of Materials Science and Engineering.
Dr. Kurtis joined Tech’s faculty in January 1999. She earned her BSE (1994) in Civil Engineering from Tulane University under a Deans Honor Scholarship and her MS (1995) and PhD (1998) in Civil Engineering from the University of California at Berkeley, where she was a Henry Hilp Fellow and a National Science Foundation (NSF) Fellow. Dr. Kurtis’s innovative research on the multi-scale structure and performance of cement-based materials has resulted in more than 200 technical publications, as well as three US patents. Her group is particularly recognized its use of emerging methods and novel approaches to provide new fundamental insights into the behavior of cement pastes, mortars, and concretes necessary for improving their early age behavior and long-term durability.
She has held two leadership positions – Chairman of ACI Committee 236: Materials Science of Concrete (2006-2012) and Chair of American Ceramic Society’s Cements Division (2008-2009) – central to advancing science-based research on cement-based materials. Dr. Kurtis has served as Associate Editor of ASCE Journal of Materials in Civil Engineering and on the Editorial Board of Cement and Concrete Composites. Currently, she is Editorial Board member for Cement and Concrete Research and serves on the American Concrete Institute’s Board of Directors. She has been honored with ACI’s Walter P. Moore, Jr. Faculty Achievement Award (2005), ACI’s Del Bloem Award for Service (2013), Outstanding Senior Undergraduate Research Mentor Award at Georgia Institute of Technology (2013), the ACI James Instruments Award for Research on NDE of Concrete (2008), Award for Outstanding Article in ASTM’s Journal of Testing and Evaluation (2010), ASCE’s Huber Civil Engineering Research Prize (2013), and ACI’s Anderson Medal (2018). Dr. Kurtis is Fellow of the American Concrete Institute and the American Ceramics Society.
About Purebase Corporation
Purebase Corporation (OTCQB: PUBC) is a diversified resource company that acquires, develops and markets minerals for use in the agriculture, construction and other specialty industries.
Contacts
Emily Tirapelle - Purebase Corporation | emily.tirapelle@purebase.com, and please visit our corporate website and subscribe to our upcoming Newsletter – www.purebase.com/newsletter
Safe Harbor
This press release contains statements, which may constitute “forward-looking statements.”. Those statements include statements regarding the intent, belief, or current expectations of Purebase Corporation and members of its management team as well as the assumptions on which such statements are based. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that may cause actual results to differ from those anticipated are discussed throughout the Company’s reports filed with Securities and Exchange Commission which are available at www.sec.gov as well as the Company’s web site at www.purebase.com. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.